Clusterin is regulated by IGF1–PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity

Changes to the Human Serum Proteome in Response to High Intensity Interval Exercise: A Sequential Top-Down Proteomic Analysis

(2019) Nigel Kurgan et al.   Frontiers in Physiology

Targeting clusterin induces apoptosis, reduces growth ability, invasion and mediates sensitivity to chemotherapy in human cancer in human osteosarcoma cells

(2019) Xiaohui Wang et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer

(2019) Hoter et al.   Cancers

Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction

(2018) Annie Turkieh et al.   Circulation-Heart Failure

Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling

(2018) Bianca C. Bernardo et al.   CLINICAL SCIENCE

Molecular Atlas of Postnatal Mouse Heart Development

(2018) Virpi Talman et al.   Journal of the American Heart Association

Protective molecular mechanisms of clusterin against apoptosis in cardiomyocytes

(2017) Rodrigo Martins Pereira et al.   HEART FAILURE REVIEWS

Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure

(2017) Lorenz Koller et al.   Journal of Clinical Lipidology

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

(2017) Kim N Chi et al.   LANCET ONCOLOGY

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

(2017) Tomasz M Beer et al.   LANCET ONCOLOGY

Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload

(2016) Bianca C. Bernardo et al.   Scientific Reports

Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy

(2014) Bianca C. Bernardo et al.   FASEB JOURNAL

The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice

(2014) Geeta Sapra et al.   Nature Communications

The Molecular Chaperone Apolipoprotein J/Clusterin as a Sensor of Oxidative Stress: Implications in Therapeutic Approaches - A Mini-Review

(2013) Ioannis P. Trougakos   GERONTOLOGY

Phosphoinositide 3-Kinase p110α Is a Master Regulator of Exercise-Induced Cardioprotection and PI3K Gene Therapy Rescues Cardiac Dysfunction

(2012) Kate L. Weeks et al.   Circulation-Heart Failure

IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin

(2012) XIUMEI MA et al.   Molecular Medicine Reports

Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function

(2012) B. C. Bernardo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosisviaAkt/GSK-3β signaling pathway

(2011) Hyoung-Oh Jun et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

PI3K(p110α) Protects Against Myocardial Infarction-Induced Heart Failure

(2010) Ruby C.Y. Lin et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation

(2009) Lynette Pretorius et al.   AMERICAN JOURNAL OF PATHOLOGY

Cancer Cell-Derived Clusterin Modulates the Phosphatidylinositol 3'-Kinase-Akt Pathway through Attenuation of Insulin-Like Growth Factor 1 during Serum Deprivation

(2008) H. Jo et al.   MOLECULAR AND CELLULAR BIOLOGY